1-4 of 4
J. Silvio Gutkind
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited irAEs

Mara Gilardi, Robert Saddawi-Konefka, Victoria H. Wu, Miguel Angel Lopez-Ramirez, Zhiyong Wang, Fernando Soto, Dana J. Ramms, Marco Proietto, Zbigniew Mikulski, Haruka Miki, Andrew Sharabi, Daniel Kupor, Ricardo Rueda, Daniel P. Hollern, Joseph Wang, J. Silvio Gutkind
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (4): 616–624.
https://doi.org/10.1158/1535-7163.MCT-21-0234
Published: 01 April 2022
View article titled, Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited irAEs
Open the PDF for Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited irAEs in another window
Includes: Supplementary data
Journal Articles

Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas

Mara Gilardi, Zhiyong Wang, Marco Proietto, Anastasia Chillà, Juan Luis Calleja-Valera, Yusuke Goto, Marco Vanoni, Matthew R. Janes, Zbigniew Mikulski, Antonio Gualberto, Alfredo A. Molinolo, Napoleone Ferrara, J. Silvio Gutkind, Francis Burrows
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2020) 19 (9): 1784–1796.
https://doi.org/10.1158/1535-7163.MCT-19-0958
Published: 02 September 2020
View article titled, Tipifarnib as a Precision Therapy for <em>HRAS</em>-Mutant Head and Neck Squamous Cell Carcinomas
Open the PDF for Tipifarnib as a Precision Therapy for <em>HRAS</em>-Mutant Head and Neck Squamous Cell Carcinomas in another window
Includes: Supplementary data
Journal Articles

Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that PTEN Loss Contributes to Cetuximab Resistance in Head and Neck Cancer

Hiroki Izumi, Zhiyong Wang, Yusuke Goto, Toshinori Ando, Xingyu Wu, Xuefeng Zhang, Hua Li, Daniel E. Johnson, Jennifer R. Grandis, J. Silvio Gutkind
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (7): 1562–1571.
https://doi.org/10.1158/1535-7163.MCT-19-1036
Published: 02 July 2020
View article titled, Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that <em>PTEN</em> Loss Contributes to Cetuximab Resistance in Head and Neck Cancer
Open the PDF for Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that <em>PTEN</em> Loss Contributes to Cetuximab Resistance in Head and Neck Cancer in another window
Includes: Supplementary data
Journal Articles

Keratin down-regulation in vimentin-positive cancer cells is reversible by vimentin RNA interference, which inhibits growth and motility

Rachel J. Paccione, Hiroshi Miyazaki, Vyomesh Patel, Ahmad Waseem, J. Silvio Gutkind, Zendra E. Zehner, W. Andrew Yeudall
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (9): 2894–2903.
https://doi.org/10.1158/1535-7163.MCT-08-0450
Published: 11 September 2008
View article titled, Keratin down-regulation in vimentin-positive cancer cells is reversible by vimentin RNA interference, which inhibits growth and motility
Open the PDF for Keratin down-regulation in vimentin-positive cancer cells is reversible by vimentin RNA interference, which inhibits growth and motility in another window
Includes: Supplementary data